The MYCN oncoprotein as a drug development target - PubMed

Review

The MYCN oncoprotein as a drug development target

Xiaohong Lu et al. Cancer Lett. 2003.

Abstract

The transcription factor and proto-oncogene MYCN is reviewed as a potential specific target for cancer therapy. Amplification of MYCN is frequently found in a number of advanced-stage tumours, including neuroblastoma (25%), small cell lung cancers (7%), alveolar rhabdomyosarcoma and retinoblastoma. It is associated with rapid tumour progression and poor outcome in human neuroblastoma. MYCN is a member of the myc family of proto-oncogenes which encode nuclear proteins that form heterodimers with MAX protein through their conserved HLHZip domains. The MYC/MAX complexes transactivate a number of MYC-target genes in a sequence-specific manner. MYC-MAX interaction is essential for MYC-induced cell cycle progression, cellular transformation, and transcriptional activation. A causal link between the transformed phenotype and MYCN has been established by a range of in vitro and in vivo studies, including a transgenic model of neuroblastoma in which MYCN overexpression is targeted to neuronal tissue by the use of a tyrosine hydroxylase promoter. Downregulation of MYCN expression either by antisense treatment targeted against MYCN mRNA or by retinoids has been shown to decrease proliferation and/or induce neuronal differentiation of neuroblastoma cells. Inhibition of MYC-MAX dimerisation by small-molecule antagonists has recently been shown to interfere with MYC-induced transformation of chick embryo fibroblasts, indicating that functional inhibitors of the MYC family of oncoproteins have potential as therapeutic agents. Finally, we describe the development and validation of a functional MYCN reporter gene assay using neuroblastoma cells (NGP) which have been stably transfected with a luciferase gene construct under control of the ornithine decarboxylase gene promoter. This assay has been used for a pilot screen of 2800 compounds from the Cancer Research-UK collection, identifying five compounds showing a consistent significant reduction of MYCN-dependent luciferase activity (>50%) in repeated screens. This cell-based, MYCN reporter gene assay will be scaled up for high throughput screens of compound libraries and will aid in the future development of specific therapeutic strategies in neuroblastoma and other tumours in which MYCN amplification has been implicated.

Similar articles

• Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.

  Cetinkaya C, Hultquist A, Su Y, Wu S, Bahram F, Påhlman S, Guzhova I, Larsson LG. Cetinkaya C, et al. Mol Cancer Ther. 2007 Oct;6(10):2634-41. doi: 10.1158/1535-7163.MCT-06-0492. Mol Cancer Ther. 2007. PMID: 17938259

• MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.

  Slack AD, Chen Z, Ludwig AD, Hicks J, Shohet JM. Slack AD, et al. Cancer Res. 2007 Mar 15;67(6):2448-55. doi: 10.1158/0008-5472.CAN-06-1661. Cancer Res. 2007. PMID: 17363562

• TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma.

  Selmi A, de Saint-Jean M, Jallas AC, Garin E, Hogarty MD, Bénard J, Puisieux A, Marabelle A, Valsesia-Wittmann S. Selmi A, et al. Cancer Lett. 2015 Feb 1;357(1):412-418. doi: 10.1016/j.canlet.2014.11.056. Epub 2014 Dec 1. Cancer Lett. 2015. PMID: 25475555

• New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.

  Barone G, Anderson J, Pearson AD, Petrie K, Chesler L. Barone G, et al. Clin Cancer Res. 2013 Nov 1;19(21):5814-21. doi: 10.1158/1078-0432.CCR-13-0680. Epub 2013 Aug 21. Clin Cancer Res. 2013. PMID: 23965898 Free PMC article. Review.

• MYCN oncoprotein targets and their therapeutic potential.

  Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA. Bell E, et al. Cancer Lett. 2010 Jul 28;293(2):144-57. doi: 10.1016/j.canlet.2010.01.015. Epub 2010 Feb 13. Cancer Lett. 2010. PMID: 20153925 Review.

Cited by

• One-Carbon and Polyamine Metabolism as Cancer Therapy Targets.

  Islam A, Shaukat Z, Hussain R, Gregory SL. Islam A, et al. Biomolecules. 2022 Dec 19;12(12):1902. doi: 10.3390/biom12121902. Biomolecules. 2022. PMID: 36551330 Free PMC article. Review.

• Cell survival signaling in neuroblastoma.

  Megison ML, Gillory LA, Beierle EA. Megison ML, et al. Anticancer Agents Med Chem. 2013 May;13(4):563-75. doi: 10.2174/1871520611313040005. Anticancer Agents Med Chem. 2013. PMID: 22934706 Free PMC article. Review.

• The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification.

  Geerts D, Koster J, Albert D, Koomoa DL, Feith DJ, Pegg AE, Volckmann R, Caron H, Versteeg R, Bachmann AS. Geerts D, et al. Int J Cancer. 2010 May 1;126(9):2012-24. doi: 10.1002/ijc.25074. Int J Cancer. 2010. PMID: 19960435 Free PMC article.

• The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.

  Van Roy N, De Preter K, Hoebeeck J, Van Maerken T, Pattyn F, Mestdagh P, Vermeulen J, Vandesompele J, Speleman F. Van Roy N, et al. Genome Med. 2009 Jul 27;1(7):74. doi: 10.1186/gm74. Genome Med. 2009. PMID: 19638189 Free PMC article.

• Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth.

  Li Y, Zhang B, Zhang H, Zhu X, Feng D, Zhang D, Zhuo B, Li L, Zheng J. Li Y, et al. J Cancer Res Clin Oncol. 2013 Jun;139(6):933-41. doi: 10.1007/s00432-013-1406-4. Epub 2013 Feb 27. J Cancer Res Clin Oncol. 2013. PMID: 23443256

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information